Lucid Capital analyst Elemer Piros raised the firm’s price target on Ocugen (OCGN) to $22 from $15 and keeps a Buy rating on the shares. The company announced positive preliminary Phase 2 data for OCU410 in geographic atrophy, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OCGN:
- Ocugen’s Gene Therapy Pipeline Dominates Earnings Call
- Ocugen: Late-Stage Retinal Pipeline and 2027–2028 Approval Catalysts Underpin Buy-Rated Risk‑Reward
- Ocugen’s Growing Pains: High Execution and Compliance Risks Threaten Shareholder Value
- Ocugen Seeks Court Validation of Charter Amendment Dispute
- Ocugen reports Q4 EPS (6c), consensus (6c)